LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN.UK

13,902

-1.08%↓

Home・Akciju saraksts・AstraZeneca PLC

AstraZeneca PLC

Slēgts

SektorsVeselības aprūpe

187.25 -1.32

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

186.99

Max

188.07

Galvenie mērījumi
By Trading Economics
Ienākumi	1.6B 3.9B
Pārdošana	-215M 15B
P/E Sektora vidējais	27.887 49.701
EPS	1.29
Dividenžu ienesīgums	1.74
Peļņas marža	25.602
Darbinieki	96,100
EBITDA	1.1B 5.7B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+15.53% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	1.74% 2.39%
Nākamie ieņēmumi	2026. g. 27. jūl.
Nākamais Ex dividenžu datums	2026. g. 6. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-3.5B 287B
Iepriekšējā atvēršanas cena	188.57
Iepriekšējā slēgšanas cena	187.25

Ziņu noskaņojums

By Acuity

50%

146 / 345 Rangs Healthcare

AstraZeneca PLC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 29. apr. 16:28 UTC

Peļņas

Correction to AstraZeneca Update

2026. g. 29. apr. 15:11 UTC

Peļņas

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

2026. g. 29. apr. 06:31 UTC

Peļņas

AstraZeneca Gets Revenue Boost From Cancer Drugs

2026. g. 21. maijs 11:06 UTC

Tirgus saruna

AstraZeneca Set for Busy End of Year -- Market Talk

2026. g. 13. maijs 12:29 UTC

Tirgus saruna

AstraZeneca Has Room to Grow in Heart Disease With Wainua -- Market Talk

2026. g. 13. maijs 11:54 UTC

Tirgus saruna

AstraZeneca Has Credible Growth Path Beyond 2030 -- Market Talk

2026. g. 1. maijs 09:31 UTC

Tirgus saruna

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

2026. g. 29. apr. 10:29 UTC

Tirgus saruna

Peļņas

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

2026. g. 29. apr. 10:06 UTC

Tirgus saruna

Peļņas

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

2026. g. 29. apr. 09:53 UTC

Tirgus saruna

Peļņas

AstraZeneca Seems in Fine Health -- Market Talk

2026. g. 29. apr. 06:05 UTC

Peļņas

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

2026. g. 29. apr. 06:04 UTC

Peļņas

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

2026. g. 29. apr. 06:04 UTC

Peļņas

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

2026. g. 29. apr. 06:03 UTC

Peļņas

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

2026. g. 29. apr. 06:03 UTC

Peļņas

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

2026. g. 29. apr. 06:02 UTC

Peļņas

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

2026. g. 29. apr. 06:01 UTC

Peļņas

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

2026. g. 29. apr. 06:01 UTC

Peļņas

AstraZeneca Backs 2026 View

2026. g. 29. apr. 06:00 UTC

Peļņas

AstraZeneca PLC 1Q Adj EPS $2.58

2026. g. 29. apr. 06:00 UTC

Peļņas

AstraZeneca PLC 1Q Rev $15.29B

2026. g. 29. apr. 06:00 UTC

Peļņas

AstraZeneca PLC 1Q Pretax Pft $3.91B

2026. g. 29. apr. 06:00 UTC

Peļņas

AstraZeneca PLC 1Q Oper Pft $4.25B

2026. g. 29. apr. 06:00 UTC

Peļņas

AstraZeneca PLC 1Q Net Pft $3.08B

2026. g. 29. apr. 06:00 UTC

Peļņas

AstraZeneca PLC 1Q EPS $1.97

2026. g. 27. apr. 10:48 UTC

Tirgus saruna

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

2026. g. 10. apr. 11:57 UTC

Tirgus saruna

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

2026. g. 10. apr. 10:26 UTC

Tirgus saruna

Peļņas

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

2026. g. 2. apr. 09:16 UTC

Tirgus saruna

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

2026. g. 27. marts 10:40 UTC

Tirgus saruna

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

2026. g. 27. marts 10:17 UTC

Tirgus saruna

AstraZeneca Lung Disease Trial Adds Building Block to 2030 Target -- Market Talk

Salīdzinājums

Cenas izmaiņa

AstraZeneca PLC Prognoze

Cenas mērķis

By TipRanks

15.53% augšup

Prognoze 12 mēnešiem

Vidējais 216.074 USD 15.53%

Augstākais 249.984 USD

Zemākais 151.872 USD

Pamatojoties uz 15 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AstraZeneca PLC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

15 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 15 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam AstraZeneca PLC — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

146 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.